<u>**Answering Reviewers**</u>

Dear Editor:

Thank you for your careful review of our manuscript entitled, "Lenvatinib for two cases of large hepatocellular carcinomas with portal trunk invasion: case reports" (Manuscript NO: 55463).

We have read the reviewers' comments carefully and have revised the manuscript accordingly. The revised portions in the manuscript are in red font. We have also given point-by-point responses to the reviewers' comments, as follows.

Responses to Reviewers' comments:

Responses to *Reviewer 1:*
Reviewer #05038583 thinks that this case report is interesting and highlights the promising results of lenvatibinb therapy although current NCCN guideline states both sorafenib or lenvatinib can be considered for the first line therapy, and suggests the authors to make a minor revision accordingly
Thank you for your comment. We have added a sentence explaining the recommendations of the NCCN guideline for the treatment of hepatocellular carcinoma in the Introduction section (page 8, line 15-18 of the revised manuscript).

Responses to *Reviewer 2:*
Reviewer #02439165 suggests the authors to short the introduction.
Thank you for your valuable comment. As suggested by you, we have shortened the Introduction section, while focusing on the poor prognostic factors and the expected efficacy of lenvatinib treatment in BCLC stage C hepatocellular carcinoma patients.

Others
We have added Hiroyuki Fukuda newly to the authors, because he was the patient`s internist and reviewed the literature and drafted the manuscript.

We trust that these revisions are satisfactory and that you will now find the manuscript acceptable for publication in *World Journal of Clinical Cases.*

We thank you again for reviewing our manuscript, and hope to receive a favorable reply at your earliest convenience.

Sincerely yours,

Kazushi Numata, M.D.
Gastroenterological Center, Yokohama City University Medical Center,
4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, Japan
E-mail: kz-numa@urahp.yokohama-cu.ac.jp